Renal implications of systemic lupus erythematosus pathogenesis and treatment⁠

INTRODUCTION

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by multisystem involvement and the production of autoantibodies, particularly antinuclear antibodies (ANAs). Among its diverse clinical manifestations, lupus nephritis (LN) is a severe complication that arises in approximately 50% of SLE patients and remains a leading cause of morbidity and mortality. The renal involvement in LN encompasses a spectrum of immune complex-mediated glomerular and tubular injuries, often leading to progressive kidney damage and, in some cases, end-stage renal disease.¹

The pathogenesis of SLE involves a complex interplay of genetic, epigenetic, environmental, and immunological factors. Genetic predispositions, including mutations in genes regulating immune tolerance and complement activation, are pivotal in the disease's onset. Environmental triggers such as ultraviolet light and infections further exacerbate immune dysregulation. In LN, the deposition of immune complexes in renal tissues triggers inflammation and complement activation, culminating in tissue damage.²

Current therapeutic approaches for LN focus on immunosuppression to mitigate renal inflammation and prevent progression to chronic kidney disease. Agents such as corticosteroids, cyclophosphamide, and mycophenolate mofetil have been mainstays of treatment. However, these therapies are associated with significant adverse effects, including increased risk of infections and organ toxicity. Recent advances in understanding the molecular and cellular mechanisms of LN have paved the way for targeted therapies, including B-cell depleting agents like rituximab and complement inhibitors, which aim to offer efficacy with a better safety profile.³

Despite these advances, several challenges remain in the management of LN. Heterogeneity in clinical presentations and histopathological patterns complicates diagnosis and treatment decisions. Moreover, the development of biomarkers for disease activity and treatment response is still in its infancy. These limitations underscore the need for a deeper understanding of the pathophysiology and novel therapeutic strategies tailored to the diverse manifestations of LN.⁴ This review aims to provide a comprehensive overview of the renal implications of SLE, exploring the underlying pathogenic mechanisms, current treatment modalities, and emerging directions in lupus nephritis research.

REVIEW

LN is a severe manifestation of SLE and remains a significant challenge due to its complex pathogenesis and varied clinical presentation. Central to LN's pathology is the deposition of immune complexes in renal tissues, which activates complement pathways and triggers a cascade of inflammatory responses. This inflammatory milieu leads to damage in glomerular and tubular structures, ultimately impairing kidney function. Advances in understanding the molecular underpinnings of LN have identified key mediators, such as cytokines and immune effector cells, that sustain this chronic inflammatory process.⁵

Therapeutically, LN management has evolved with the advent of targeted biologics, including B-cell depleting agents and complement inhibitors. These therapies aim to provide efficacy with reduced toxicity compared to traditional immunosuppressants like cyclophosphamide and corticosteroids. However, response to treatment is highly variable, with many patients failing to achieve complete remission. Recent studies highlight the need for biomarkers that can guide personalized treatment approaches and predict long-term outcomes in LN patients.⁶ Despite therapeutic progress, the burden of LN-associated morbidity remains high, particularly in populations with limited access to specialized care. These disparities emphasize the importance of integrating novel therapies with strategies to improve access and equity in LN management.

Pathogenic mechanisms linking SLE to lupus nephritis

The development of LN in SLE is an intricate process driven by a convergence of immune dysregulation, environmental triggers, and genetic susceptibility. Immune complexes, primarily composed of nucleic acid-containing antigens and autoantibodies, play a central role in this pathology. Their deposition in renal tissues initiates complement activation, which fuels local inflammation and subsequent damage to glomerular and tubular structures. This cascade is mediated by pro-inflammatory cytokines such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α), which amplify the recruitment and activation of immune cells within renal tissues.⁷

Toll-like receptors (TLRs) have emerged as critical mediators in SLE pathogenesis, particularly in LN. TLR7 and TLR9 recognize nucleic acid-containing immune complexes, leading to the activation of plasmacytoid dendritic cells and the release of type I interferons (IFNs). Type I IFNs, in turn, enhance B-cell differentiation and antibody production, creating a feedback loop that sustains autoimmunity and promotes renal injury. The dysregulation of TLR signaling pathways has been linked to increased severity of nephritis in murine models, providing a compelling target for therapeutic intervention.⁸

The complement system further exacerbates renal damage through its amplification of inflammatory responses. Complement components C3 and C5, as well as their activation fragments, are frequently detected in renal biopsies of LN patients. C5a, a potent anaphylatoxin, recruits neutrophils and monocytes to the kidney, where they contribute to tissue damage through the release of reactive oxygen species and proteolytic enzymes. Inhibition of complement activation has shown promise in reducing renal inflammation and preserving kidney function in preclinical studies.⁹

The role of podocytes, specialized cells critical for maintaining the glomerular filtration barrier, has gained attention in LN pathogenesis. Autoantibodies targeting podocyte-specific proteins disrupt cytoskeletal organization and cell adhesion, leading to podocyte detachment and proteinuria. The loss of podocytes is a hallmark of glomerular injury in LN and correlates with disease progression. Mechanistic studies highlight the involvement of actin cytoskeletal dysregulation and apoptosis in podocyte injury, offering insights into potential therapeutic strategies to protect these cells.¹⁰

Epigenetic modifications, including DNA methylation and histone acetylation, also contribute to the pathogenesis of LN. Aberrant DNA methylation patterns have been observed in genes regulating immune responses, resulting in the overexpression of pro-inflammatory cytokines and autoantibodies. In addition, histone modifications influence chromatin accessibility, impacting the expression of genes involved in immune regulation and renal homeostasis. Targeting these epigenetic pathways with small molecule inhibitors has emerged as a novel approach to modulate autoimmune responses and mitigate kidney damage in SLE.¹¹

Gut microbiota composition and its interaction with the host immune system have recently been implicated in LN. Dysbiosis, characterized by reduced diversity and an overrepresentation of pathogenic bacterial species, alters the gut-renal axis. Microbial metabolites, including short-chain fatty acids, modulate immune cell differentiation and inflammatory responses. Emerging evidence suggests that restoring gut microbial balance through probiotics or dietary interventions may attenuate systemic inflammation and improve renal outcomes in LN patients.¹²

Therapeutic strategies in managing renal involvement in SLE

LN is considered one of the most serious complications of SLE and necessitates a multifaceted and individualized approach to treatment. The management of LN has progressively evolved, integrating traditional immunosuppressive therapies with novel biologics and adjunctive strategies that target specific immune pathways implicated in the disease. Early and precise intervention is critical to preserve renal function and mitigate the risk of progression to chronic kidney disease or end-stage renal disease. Immunosuppressive therapies form the foundation of LN management. Glucocorticoids, in combination with agents such as cyclophosphamide or mycophenolate mofetil, are commonly employed to induce and maintain remission. While cyclophosphamide has demonstrated efficacy in severe cases, its long-term use is often limited by toxicity, including infertility and secondary malignancies. Mycophenolate mofetil has emerged as a safer and equally effective alternative, particularly for women of childbearing age, and remains a first-line option for induction and maintenance therapy in LN.¹³ Advances in dosing protocols have also optimized the use of these agents, balancing efficacy and adverse effect profiles.

The introduction of biologics has revolutionized the therapeutic landscape of LN. Targeted therapies such as belimumab, a monoclonal antibody that inhibits B-cell activating factor, have shown promising results in reducing disease activity and maintaining remission. Studies reveal that belimumab improves renal outcomes when used alongside standard therapy, particularly in patients with active lupus nephritis. Similarly, rituximab, which targets CD20-positive B cells, has demonstrated efficacy in refractory cases, offering hope for patients who do not respond to conventional immunosuppression.¹⁴ The success of these therapies underscores the importance of targeting B-cell-mediated autoimmunity in LN pathogenesis.

Complement inhibitors represent another innovative approach in LN treatment. The complement system, particularly the activation of C3 and C5, plays a pivotal role in driving inflammation and tissue injury in lupus nephritis. Eculizumab, a C5 inhibitor, and other agents targeting various components of the complement cascade have shown efficacy in preclinical and early clinical studies. These therapies aim to reduce renal inflammation and protect against complement-mediated damage, offering a new dimension of therapeutic potential for LN management.¹⁵ Sodium-glucose co-transporter-2 (SGLT2) inhibitors, originally developed for diabetes, have emerged as a novel adjunctive therapy for LN. Beyond their glycemic control benefits, SGLT2 inhibitors exert renoprotective effects by reducing intraglomerular pressure and proteinuria. Clinical studies suggest that these agents improve renal outcomes in patients with LN, particularly when combined with immunosuppressive therapy. Their cardiovascular protective properties further enhance their appeal in managing the systemic complications of SLE.¹⁶

Personalized medicine is becoming an integral part of LN treatment, driven by advances in biomarker research. Biomarkers such as urinary monocyte chemoattractant protein-1 (MCP-1) and serum levels of anti-dsDNA antibodies provide valuable insights into disease activity and treatment response. Utilizing these biomarkers allows clinicians to tailor therapies to individual patients, maximizing efficacy while minimizing unnecessary exposure to potentially harmful medications.¹⁷ The application of genetic profiling and molecular diagnostics also holds promise in identifying high-risk patients and predicting treatment outcomes.

Lifestyle modifications and adjunctive therapies complement pharmacological approaches in LN management. Controlling hypertension and proteinuria through the use of angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) is critical for renal protection. Dietary interventions, such as sodium restriction and adequate protein intake, contribute to long-term renal health. Addressing comorbidities, including cardiovascular disease and infections, is essential to improving overall outcomes in LN patients.¹⁸ Patient education and adherence to treatment regimens play a crucial role in achieving therapeutic goals, emphasizing the need for a multidisciplinary approach to care. Despite these advancements, challenges remain in the treatment of LN. The heterogeneity of the disease, coupled with disparities in access to care and treatment adherence, continues to impact outcomes. Ongoing research into novel therapeutic targets, including IL-23 inhibitors and regulatory T-cell therapies, offers hope for addressing these challenges and improving the quality of life for patients with LN.

Emerging biomarkers and future directions in lupus nephritis research

Biomarker research in LN is rapidly advancing, driven by the need for tools that provide early diagnosis, reliable monitoring, and predictive insights into therapeutic responses. Traditional clinical markers, such as serum creatinine and proteinuria, often fall short in sensitivity and specificity, leading to delays in treatment adjustments and suboptimal patient outcomes. As a result, recent efforts have focused on identifying molecular, genetic, and metabolic markers that can offer more precise insights into LN pathogenesis and activity.

Urinary biomarkers are at the forefront of this research due to their non-invasive nature and strong correlation with renal pathology. Activation products of the complement system, such as C3a, C3d, and Bb, have demonstrated robust associations with LN disease activity. These molecules reflect immune activation within the kidneys and provide dynamic insights into ongoing inflammation. In clinical trials, their levels have been shown to predict treatment response, indicating their utility as markers for therapeutic efficacy.¹² Another promising urinary biomarker is MCP-1 which is being studied for its ability to signal renal inflammation and differentiate active disease from remission phases.

Advances in microRNA (miRNA) research have revealed their potential as both biomarkers and therapeutic targets in LN. MicroRNAs regulate gene expression and are implicated in immune dysregulation. For example, miR-146a and miR-21 are found to be dysregulated in LN patients and are linked to inflammatory pathways involved in kidney injury. Their measurable presence in blood and urine makes them accessible for monitoring disease progression. Furthermore, experimental models suggest that modulating these miRNAs could reduce inflammation and fibrosis, opening avenues for novel therapeutic strategies.¹⁹

Genomic studies are shedding light on LN susceptibility and disease mechanisms, highlighting genetic variants that predispose individuals to severe renal involvement. Single nucleotide polymorphisms in immune-related genes, such as IRF5, STAT4, and TNFSF13B, have been identified as significant risk factors. These genetic markers not only help in understanding the hereditary component of LN but also guide personalized therapeutic interventions. Moreover, research on epigenetic changes, such as DNA methylation and histone modifications, reveals how environmental factors interact with the genome to influence LN severity. Epigenetic profiles could soon become integral to predicting disease outcomes and tailoring treatments.⁸

Metabolomics, the comprehensive study of small molecules within biological systems, is emerging as a valuable tool in LN research. Distinct metabolic signatures have been identified in LN patients, reflecting the unique biochemical environment of inflamed kidneys. Altered levels of tricarboxylic acid cycle intermediates and elevated markers of oxidative stress have been reported. These changes not only reveal insights into disease mechanisms but also present opportunities for targeted interventions. By combining metabolomic data with clinical findings, researchers aim to develop biomarkers that offer both diagnostic and prognostic value.²⁰

Proteomic studies further expand the biomarker landscape, identifying proteins associated with renal damage and repair processes. High-throughput technologies have uncovered markers such as neutrophil gelatinase-associated lipocalin and kidney injury molecule-1, which are closely linked to active LN. These proteins are not only indicators of kidney injury but also predictors of disease progression. Longitudinal studies are underway to validate their role in guiding treatment decisions and improving patient outcomes.⁵

Artificial intelligence (AI) and machine learning are transforming biomarker discovery by enabling the analysis of complex datasets. By integrating genomic, proteomic, and metabolomic data, AI-driven models can identify novel biomarker combinations and predict disease trajectories with remarkable accuracy. These technologies hold promise for revolutionizing LN management by facilitating personalized medicine and optimizing resource allocation in clinical settings.²¹ AI applications are also being explored for their ability to enhance clinical trial designs, accelerating the validation of new biomarkers and therapeutic targets. As biomarker research continues to advance, the integration of multidisciplinary approaches will be critical. Combining molecular, genetic, and computational tools offers a holistic view of LN, paving the way for precision medicine that not only improves patient outcomes but also reduces the burden of this complex disease.

CONCLUSION

In lupus nephritis research, emerging biomarkers offer transformative potential for early diagnosis, monitoring, and personalized treatment. Advances in genomics, proteomics, and metabolomics are enhancing our understanding of disease mechanisms while driving precision medicine. The integration of these biomarkers into clinical practice promises improved patient outcomes. Ongoing multidisciplinary efforts will be essential to fully harness these advancements.

Funding: No funding sources

Conflict of interest: None declared

Ethical approval: Not required

REFERENCES

1. 1. Mok C, Lau C. Pathogenesis of systemic lupus erythematosus. J Clin Pathol. 2003;56(7):481-90.
2. 2. Ahearn JM, Liu C-C, Kao AH, Manzi S. Biomarkers for systemic lupus erythematosus. Transl Res. 2012;159(4):326-42.
3. 3. Tsao B. Genetic susceptibility to lupus nephritis. Lupus. 1998;7(9):585-90.
4. 4. Zhang Y, Gan L, Tang J, Liu D, Chen G, Xu B. Metabolic profiling reveals new serum signatures to discriminate lupus nephritis from systemic lupus erythematosus. Front Immunol. 2022;13:967371.
5. 5. Aljaberi N, Bennett M, Brunner HI, Devarajan P. Proteomic profiling of urine: implications for lupus nephritis. Exp Rev Proteom. 2019;16(4):303-13.
6. 6. Fava A, Petri M. Systemic lupus erythematosus: diagnosis and clinical management. J Autoimmun. 2019;96:1-13.
7. 7. Nozaki Y, Hao Y, Barnas JL. Treat-to-target in systemic lupus erythematosus: cytokine transduction pathways in SLE. Front Immunol. 2024;15:1503776.
8. 8. Rajappa MC, Muthumani K, Soosai JKM, Vezhaventhan V, Solomon GG, Gnanamoorthi S. Reviewing Genetic Testing for Lupus: Implications for Nephritis. Biomed Pharmacol J. 2024;17(3):1395-405.
9. 9. Stafford IS, Kellermann M, Mossotto E, Beattie RM, MacArthur BD, Ennis S. A systematic review of the applications of artificial intelligence and machine learning in autoimmune diseases. NPJ Digital Med. 2020;3(1):30.
10. 10. Wolf BJ, Spainhour JC, Arthur JM, Janech MG, Petri M, Oates JC. Development of biomarker models to predict outcomes in lupus nephritis. Arthritis Rheumatol. 2016;68(8):1955-63.
11. 11. Mok CC. Biomarkers for lupus nephritis: a critical appraisal. BioMed Res Int. 2010;2010(1):638413.
12. 12. Reyes-Thomas J, Blanco I, Putterman C. Urinary biomarkers in lupus nephritis. Clin Rev Allergy Immunol. 2011;40:138-50.
13. 13. Palazzo L, Lindblom J, Mohan C, Parodis I. Current insights on biomarkers in lupus nephritis: a systematic review of the literature. J Clin Med. 2022;11(19):5759.
14. 14. Kraaij T, Huizinga TW, Rabelink TJ, Teng YO. Belimumab after rituximab as maintenance therapy in lupus nephritis. Rheumatology. 2014;53(11):2122-4.
15. 15. Bao L, Cunningham PN, Quigg RJ. Complement in lupus nephritis: new perspectives. Kidney Dis. 2015;1(2):91-9.
16. 16. Morales E, Galindo M. SGLT2 inhibitors in lupus nephropathy, a new therapeutic strategy for nephroprotection. Ann Rheumat Dis. 2022;81(9):1337-8.
17. 17. Alharazy S, Kong N, Mohd M, Shah S, Báin A, Gafor AA. Urinary monocyte chemoattractant protein and lupus nephritis activity. J Clin Cell Immunol. 2014;5(1):187.
18. 18. Parikh S, Hebert L, Rovin B. Protecting the kidneys in lupus nephritis. Int J Clin Rheumatol. 2011;6(5):529.
19. 19. Zhang Sj, Xu Ry, Kang Ll. Biomarkers for systemic lupus erythematosus: A scoping review. Immun Inflamm Dis. 2024;12(10):e70022.
20. 20. Kalantari S, Chashmniam S, Nafar M, Zakeri Z, Parvin M. Metabolomics approach reveals urine biomarkers and pathways associated with the pathogenesis of lupus nephritis. Iran J Basic Med Sci. 2019;22(11):1288.
21. 21. Vivas AJ, Boumediene S, Tobón GJ. Predicting autoimmune diseases: A comprehensive review of classic biomarkers and advances in artificial intelligence. Autoimmun Rev. 2024;103611.

⁠